TraffikGene-Tx (101113110)

Horizon EuropeEIC Transition Challenges RNA therapeutics for complex and rare genetics deseases: Targeted Peptide Carriers for RNA Delivery. Amount: €2,499,999. From 01/06/2023 to 31/07/2026. 

CAR T-REX (Collaborative Project: 101099867 )

Horizon EuropeEIC Pathfinder Open. CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment. Total Project amount: € 2,733,931.25 (Individual funding: € 560,512.50). From 01/04/2023 to 31/03/2027. 

TraffikGene (IN855A 2021/06) 

Ignicia Prueba de Concepto. Xunta de Galicia and Fundación Barrié. TraffikGene: new peptide vehicles for gene therapy applications. Amount: €498,000. From 01/01/2022 to 31/05/2024. 

axencioa galega innovacion

GeneVector (PDC2021-121192-I00)

Spanish AEI: Prueba de Concepto. A New Chemical Platform for Customized Gene Therapy. Amount: €150,000. From 01/12/2021 to 31/07/2024.

CARRIER (PID2020-117143RB-100) 

Spanish AEI: Proyectos I+D+i. Conceptually new chemical tools for the next generation of nucleic acid delivery vehicles. Amount: €242,000. From 01/09/2021 to 31/08/2024. 


Biotech incubator sponsored by the University of Santiago de Compostela, Uninova, and Cámara de Comercio de Santiago. Remote pre-incubation modality. 2021.

Spin-UP project

Programa INTERREG V-A España – Portugal (POCT EP) 2014-2020. Acceleration and mentorship activities for deep tech entrepreneurship initiatives in the Galician and North of Portugal regions. 2021 to June 2022.

ISCIII (COV20/00297) 

Spanish Carlos III Health Institute. Support for the investigation of the technology application for SARS-CoV-2 mRNA vaccination. Amount: €126,425. From 30/04/2020 to 30/08/2021.

TraffikGene (838002) 

ERC-PoC. Support for proofof-concept validation of the delivery technology discovered during DYNAP. Amount: €150,000. From 01/07/2019 to 39/06/2021. 

DYNAP (677786) 

ERC-StG. Dynamic Penetrating Peptide Adaptamers. €1,492,525. From 01/02/2016 to 31/07/2022. 

EIC Transition – TraffikGene-Tx

TraffikGene-Tx: Targeted Peptide Carriers for RNA Delivery


Rare and complex genetic diseases lead to significant disability, death and associated cost burdens for society. Nucleic acid therapeutics (NATs) represent a potential treatment, but they are hampered by the “delivery problem”. In the TraffikGene-Tx project we will further refine and validate our non-viral RNA delivery platform, which represents a safe, targetable, and scalable technology with the potential to break new ground in the field of RNA, ultimately providing access to effective, safe, and affordable advanced therapeutics for millions of patients in need.


The TraffikGene-Tx project aims to

  • Build a robust CMC and QC package around the TraffikGene platform to facilitate technology transfer to industrial settings
  • Develop an structure-activity relationship predictive tool for enhanced in vivo targeting
  • Obtain efficacy and Tox data under GLP for the first pipeline product, and establish its regulatory roadmap
  • Establish a NewCo for the commercial exploitation of the technology, making it accesible to relevant stakeholders


TraffikGene-Tx’s best-in-class nucleic acid delivery technology will enable the development of highly effective and specifically targeted NATs. TraffikGene-Tx will develop its own in-house pipeline of delivery enhanced NATs and will also make its technology available, through licensing, to others to ensure that a new generation of NATs are developed to treat serious and unmet patient medical needs effectively, safely, and affordably.


Funded by the European Union

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them.

About EIC

The European Innovation Council (EIC) was created as part of the EU Horizon Europe program. With a €10.1 billion budget, it aims to support game-changing ideas from early-stage research to proof of concept, technology transfer, and the financing and scaling-up of start-ups and SMEs. The EIC Pathfinder Open provides funding for projects in any field of science or technology based on high-risk/high-gain science-towards-technology breakthrough interdisciplinary research.

About the TraffikGene-Tx project

TraffikGene-Tx was awarded a €2.5M EIC Transition Challenges Grant (No. 101113110 ) by the European Innovation Council (EIC) to develop and advance in the marketisation of a new gene delivery platform based on peptide amphiphiles. The project started in June 2023 and will run for 3 years.

Scroll al inicio